Search research articles
Contact Us
Filters
Showing results (51-60 of 77) with videos related to
Page
of 8
Sort By:
British Journal of Cancer
|
August 26, 2020
A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours
Christophe Le Tourneau, Jean-Pierre Delord, Nuria Kotecki, et al.
Science Translational Medicine
|
June 17, 2021
Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan deposition
Stefan Bissinger, Carina Hage, Vinona Wagner, et al.
Science Translational Medicine
|
January 24, 2024
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers
Aurélien Voissière, Carlos Gomez-Roca, Sylvie Chabaud, et al.
International Journal of Cancer
|
September 1, 2019
From presentation to paper: Gender disparities in oncological research
Willemieke P M Dijksterhuis, Charlotte I Stroes, Wan-Ling Tan, et al.
JCI Insight
|
December 17, 2020
PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells
Camille-Charlotte Balança, Anna Salvioni, Clara-Maria Scarlata, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2025
Phase 1 and 2 Clinical Studies of the STING Agonist Ulevostinag With and Without Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors or Lymphomas
Kevin J Harrington, Stephane Champiat, Joshua D Brody, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 23, 2012
Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors
David Olmos, Roger P A'hern, Silvia Marsoni, et al.
Cell Reports. Medicine
|
February 11, 2025
Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers
Stephane Champiat, Elena Garralda, Vladimir Galvao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 15, 2017
Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <i>BRAF</i>-Mutant Melanoma
Jean-Pierre Delord, Caroline Robert, Marta Nyakas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 26, 2014
Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study
Victor Moreno García, David Olmos, Carlos Gomez-Roca, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 77) with videos related to
Sort By:
Page
of 8
British Journal of Cancer
|
August 26, 2020
A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours
Christophe Le Tourneau, Jean-Pierre Delord, Nuria Kotecki, et al.
Science Translational Medicine
|
June 17, 2021
Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan deposition
Stefan Bissinger, Carina Hage, Vinona Wagner, et al.
Science Translational Medicine
|
January 24, 2024
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers
Aurélien Voissière, Carlos Gomez-Roca, Sylvie Chabaud, et al.
International Journal of Cancer
|
September 1, 2019
From presentation to paper: Gender disparities in oncological research
Willemieke P M Dijksterhuis, Charlotte I Stroes, Wan-Ling Tan, et al.
JCI Insight
|
December 17, 2020
PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells
Camille-Charlotte Balança, Anna Salvioni, Clara-Maria Scarlata, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2025
Phase 1 and 2 Clinical Studies of the STING Agonist Ulevostinag With and Without Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors or Lymphomas
Kevin J Harrington, Stephane Champiat, Joshua D Brody, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 23, 2012
Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors
David Olmos, Roger P A'hern, Silvia Marsoni, et al.
Cell Reports. Medicine
|
February 11, 2025
Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers
Stephane Champiat, Elena Garralda, Vladimir Galvao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 15, 2017
Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <i>BRAF</i>-Mutant Melanoma
Jean-Pierre Delord, Caroline Robert, Marta Nyakas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 26, 2014
Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study
Victor Moreno García, David Olmos, Carlos Gomez-Roca, et al.
Page
of 8